This Article Full Text Full Text (PDF) All Versions of this Article: 90/7/3886    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Betz, M. J. Search for Related Content PubMed PubMed Citation Articles by Betz, M. J. Related Collections Adrenal and Hypertension Endocrine Oncology

Peroxisome Proliferator-Activated Receptor- Agonists Suppress Adrenocortical Tumor Cell Proliferation and Induce Differentiation

Division of Endocrinology and Diabetes (M.J.B., I.S., F.B.), Department of Internal Medicine II, University Hospital Freiburg, D-79106 Freiburg, Germany; Division of Endocrinology (M.F., S.H.), Department of Internal Medicine, University Hospital Würzburg, D-97080 Würzburg, Germany; and Department of Internal Medicine (M.R.), University Hospital Innenstadt, Ludwig-Maximilians-University, 80336 Munich, Germany

Address all correspondence and requests for reprints to: Felix Beuschlein, M.D., Division of Endocrinology and Diabetes, Department of Internal Medicine II, Hugstetter Strasse 55, D-79106 Freiburg, Germany. E-mail: beuschlein{at}medizin.ukl.uni-freiburg.de.

Context: Thiazolidinediones (TZDs) have been implemented into clinical practice for the treatment of type 2 diabetes mellitus as specific peroxisome proliferator-activated receptor (PPAR)- ligands. Moreover, recent evidence has suggested that TZDs might have favorable effects in the treatment of a variety of tumors as differentiation-inducing agents. Adrenocortical carcinoma (ACC) is a rare tumor entity with poor prognosis due to its highly malignant phenotype and lack of effective treatment options.

Objective: The purpose of this study was to investigate effects of TZDs on adrenocortical cancer cells.

Results: PPAR mRNA expression was detectable in all adrenocortical tumors including ACCs at similar levels. Furthermore, incubation of the adrenocortical tumor cell line NCI h295 with the PPAR agonist rosiglitazone led to a decrease in cell viability, a decrease of cellular proliferation, and an increase in apoptosis as well as steroidogenesis. On the molecular level, NCI h295 cells expressed higher levels of ACTH receptor (melanocortin receptor-2) mRNA upon treatment, whereas cyclin E mRNA was reduced, thus reflecting a shift toward an expression pattern found in less aggressive adrenocortical tumors in vivo. Accordingly, luciferase experiments confirmed an increased promoter activity for the melanocortin receptor-2 after stimulation with rosiglitazone. Coincubation with the specific PPAR antagonist GW9662 demonstrated the inhibition of TZD-induced increase in steroidogenesis, whereas growth suppression upon TZD treatment was not affected by GW9662.

Conclusions: Thus, both PPAR-dependent and PPAR-independent effects of TZD treatment are likely to contribute to the observed phenotypical effects on NCI h295 cells. Taken together, these data indicate that TZDs might have the potential to become an additional treatment option as differentiation-inducing agents in patients with ACC.

This article has been cited by other articles:

				U. D. Lichtenauer, I. Shapiro, K. Geiger, M. Quinkler, M. Fassnacht, R. Nitschke, K.-D. Ruckauer, and F. Beuschlein Side Population Does Not Define Stem Cell-Like Cancer Cells in the Adrenocortical Carcinoma Cell Line NCI h295R Endocrinology, March 1, 2008; 149(3): 1314 - 1322. [Abstract] [Full Text] [PDF]

				C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]

				F.-S. Chou, P.-S. Wang, S. Kulp, and J. J. Pinzone Effects of Thiazolidinediones on Differentiation, Proliferation, and Apoptosis Mol. Cancer Res., June 1, 2007; 5(6): 523 - 530. [Abstract] [Full Text] [PDF]

				M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR) Toxicol. Sci., April 1, 2006; 90(2): 269 - 295. [Abstract] [Full Text] [PDF]

				L. S. Kirschner Emerging Treatment Strategies for Adrenocortical Carcinoma: A New Hope J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 14 - 21. [Abstract] [Full Text] [PDF]

				O. Zwermann, D. M Schulte, M. Reincke, and F. Beuschlein ACTH 1-24 inhibits proliferation of adrenocortical tumors in vivo Eur. J. Endocrinol., September 1, 2005; 153(3): 435 - 444. [Abstract] [Full Text] [PDF]